Therapeutic Solutions International, Inc. announced the signing of an exclusive intellectual property license agreement with Gustave Roussy Transfert of Villejuif, France for an issued U.S. patent covering the clinically tested "Dexosome" cancer immunotherapy product. Dexosomes are exosome nanoparticles generated by dendritic cells, which have previously been used by investigators at Anosys, Inc., in collaboration with researchers at Duke University, for treatment of cancer patients as part of an FDA-cleared Phase I clinical trial. The licensed patent was invented by internationally-renowned immunologists Sebastian Amigorena, Doctor at the Curie Institute, and Laurence Zitvogel, Professor at Gustave Roussy.

While the patent was issued when licensed to Anoysis, subsequent to merger between Anosys, Inc. and Epimmune, the patent was reverted to Gustave Roussy Transfert. The patent covers means of generating therapeutically-effective dexosomes, which can act as a platform for loading any tumor antigen desired. The in-licensing of the current patent augments previously filed patent applications by TSOI, including one filed in November 2015, covering uses of exosomes to stimulate both innate and adaptive arms of the immune response.

The Company plans to leverage the experience of its newest Board Member, Dr. Thomas Ichim, to lead the Dexosome program back into clinical trials. Dr. Ichim has previously patented the manipulation of exosomes in the area of cancer therapy for alleviation of immune suppression, as well as being published in the peer-reviewed literature in this area.